Journal article icon

Journal article

Effectiveness of fludrocortisone plus hydrocortisone versus hydrocortisone alone in septic shock: a systematic review and network meta-analysis of randomized controlled trials

Abstract:

Rationale:

The use of hydrocortisone in adult patients with septic shock is controversial, and the effectiveness of adding fludrocortisone to hydrocortisone remains uncertain.

Objectives:

To assess the comparative effectiveness and safety of fludrocortisone plus hydrocortisone, hydrocortisone alone, and placebo or usual care in adults with septic shock.

Methods:

A systematic review and a Bayesian network meta-analysis of peer-reviewed randomized trials were conducted. The primary outcome was all-cause mortality at last follow-up. Treatment effects are presented as relative risks (RRs) with 95% credible intervals (CrIs). Placebo or usual care was the reference treatment.

Measurements and Main Results:

Among 7,553 references, we included 17 trials (7,688 patients). All-cause mortality at last follow-up was lowest with fludrocortisone plus hydrocortisone (RR, 0.85; 95% CrI, 0.72–0.99; 98.3% probability of superiority, moderate-certainty evidence), followed by hydrocortisone alone (RR, 0.97; 95% CrI, 0.87–1.07; 73.1% probability of superiority, low-certainty evidence). The comparison of fludrocortisone plus hydrocortisone versus hydrocortisone alone was based primarily on indirect evidence (only two trials with direct evidence). Fludrocortisone plus hydrocortisone was associated with a 12% lower risk of all-cause mortality compared with hydrocortisone alone (RR, 0.88; 95% CrI, 0.74–1.03; 94.2% probability of superiority, moderate-certainty evidence).

Conclusions:

In adult patients with septic shock, fludrocortisone plus hydrocortisone was associated with lower risk of all-cause mortality at last follow-up than placebo and hydrocortisone alone. The scarcity of head-to-head trials comparing fludrocortisone plus hydrocortisone versus hydrocortisone alone led our network meta-analysis to rely primarily on indirect evidence for this comparison. Although we undertook several sensitivity analyses and assessments, these findings should be considered while also acknowledging the heterogeneity of included trials.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1164/rccm.202310-1785oc

Authors


More by this author
Role:
Author
ORCID:
0000-0002-4978-6353
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Role:
Author
ORCID:
0000-0003-3616-0316
More by this author
Role:
Author
ORCID:
0000-0002-6595-541X


More from this funder
Funder identifier:
https://ror.org/04pw6fb54
Grant:
UL1 TR001430


Publisher:
American Thoracic Society
Journal:
American Journal of Respiratory and Critical Care Medicine More from this journal
Volume:
209
Issue:
10
Pages:
1219-1228
Publication date:
2024-01-25
Acceptance date:
2024-01-25
DOI:
EISSN:
1535-4970
ISSN:
1073-449X
Pmid:
38271488


Language:
English
Keywords:
Pubs id:
2004534
Local pid:
pubs:2004534
Deposit date:
2025-02-10

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP